论文部分内容阅读
目的探讨二甲双胍联合瑞格列奈治疗磺脲类无效的2型糖尿病临床研究。方法选69例玉溪市第三人民医院服用磺胺类药物无效的2型糖尿病患者,随机分为对照组和试验组。对照组34例,服用二甲双胍治疗;试验组35例,服用瑞格列奈联合二甲双胍治疗,两组均治疗8周。对比两组患者空腹血糖(FPG)、餐后2h血糖(2h PG)水平及糖化血红蛋白水平(HbA_(1c))等指标的变化。结果试验组总有效率94.29%高于对照组76.47%,差异有统计学意义(P<0.05)。治疗前,两组FPG、2h PG及HbA_(1c)水平比较,差异无统计学意义(P>0.05);治疗后,两组患者FPG、2h PG及HbA_(1c)水平均较本组治疗前降低(P<0.05);且治疗后,两组患者FPG、2h PG及HbA_(1c)水平比较,差异有统计学意义(P<0.05);试验组患者的不良反应发生率为22.86%低于对照组26.47%。结论使用瑞格列奈联合二甲双胍治疗服用磺脲类无效的2型糖尿病患者时,能够有效降低FPG及HbA_(1c)水平,临床疗效好。
Objective To investigate the clinical efficacy of metformin combined with repaglinide in the treatment of type 2 diabetes mellitus with no sulfonylurea. Methods Sixty-nine patients with type 2 diabetes mellitus who were taking sulfa drugs ineffectively in the Third People’s Hospital of Yuxi City were randomly divided into control group and experimental group. Control group, 34 patients were treated with metformin; 35 patients in the test group were treated with repaglinide and metformin, and both groups were treated for 8 weeks. The changes of fasting blood glucose (FPG), 2h postprandial blood glucose (2h PG) and HbA (1c) were compared between the two groups. Results The total effective rate of the experimental group was 94.29% higher than that of the control group (76.47%), the difference was statistically significant (P <0.05). Before treatment, the levels of FPG, 2h PG and HbA 1c in the two groups had no significant difference (P> 0.05). After treatment, the levels of FPG, 2h PG and HbA 1c in both groups were significantly higher than those before treatment (P <0.05). After treatment, the levels of FPG, 2h PG and HbA 1c in both groups were significantly different (P <0.05). The incidence of adverse reactions in the test group was 22.86% Control group, 26.47%. Conclusion The use of repaglinide combined with metformin in the treatment of patients with type 2 diabetes who are refractory to sulfonylurea can effectively reduce the levels of FPG and HbA 1c and has good clinical efficacy.